Plasma phosphorylated tau 217 detects amyloid-β in neuronal synuclein disease - PubMed
3 hours ago
- #pTau217
- #Neuronal Synuclein Disease
- #Amyloid-beta
- Plasma phosphorylated tau 217 (pTau217) effectively detects amyloid-beta pathology in neuronal synuclein disease (NSD).
- The study evaluated plasma biomarkers including pTau217, pTau181, Aβ42/40, GFAP, and NfL in 253 participants with NSD, Alzheimer's disease (AD), or cognitive unimpaired status.
- pTau217 showed the best diagnostic performance with an AUC of 0.92, outperforming other biomarkers.
- Applying pTau217 cut points can reduce the need for confirmatory amyloid-beta PET or CSF tests by 41-56% in clinically diagnosed Lewy body disease (LBD) patients.
- The findings support plasma pTau217 as a minimally invasive tool for identifying amyloid-beta pathology in mixed neurodegenerative diseases.